Practical NeurologyNew Delphi Consensus Guidance for the Use of Anti-Amyloid Therapies in Alzheimer Disease

✅ Guideline Update

A 9-member Delphi panel presented 65 consensus recommendations at the 2026 AAN Annual Meeting to guide anti-amyloid monoclonal antibody implementation in private neurology practice. The recommendations address patient identification, diagnostic workflow, and infrastructure barriers, not efficacy.

Clinical Considerations

• Recommendations span 7 domains: education, patient identification, assessment, treatment, monitoring, administrative considerations, and practice guidance.
• Panel endorsed blood-based biomarkers for primary care triage and, where appropriate, diagnostic confirmation and treatment eligibility.
• Guidance reflects expert consensus from 9 implementers, not formal AAN policy or standard of care.
• Maintenance therapy recommendations remain unsettled and will evolve as real-world anti-amyloid mAb data accumulate.

Practice Applications

• Recognize the guidance is expert consensus, not formal society standards or guideline-level evidence.
• Consider structured workflows for initiation, infusion logistics, and monitoring aligned with prescribing information.
• Integrate primary care education on early-stage AD recognition into local referral patterns.
• Monitor evolving society guidance for updates on maintenance dosing as real-world data mature.

More in DMT